Nihal E Mohamed, PhD
img_Nihal E Mohamed
Care Planning for Prostate Cancer Patients on Active Surveillance
Aims: To examine the feasibility of a behavioral intervention to enhance compliance with follow-up care recommendation among newly diagnosed prostate cancer patients.
Secondhand Smoke In Central And East Harlem: Understanding Cancer Survivors' And Family Caregivers' Perceptions Of The Health Consequences Of Involuntary And Voluntary Exposure To Tobacco Smoke
Aims: To examine the ways in which urologic cancer patients and their caregivers perceive environmental exposure to tobacco smoke.
Racial, Cultural, and Dyadic Relationships Factors Influencing Treatment Decisions about Active Surveillance for Localized Prostate Cancer
Aims: To examine racial, cultural, and dyadic factors that influence men’s decisions about and adherence to active surveillance following prostate diagnosis.
Novel Approach to Enhance Ostomy Care in Bladder and Colorectal Cancer Patients
Aims: To design and evaluate the acceptability and feasibility of an intervention to enhance ostomy care in bladder and colorectal cancer patients.
Examining Unmet Needs Among Bladder Cancer Patients
Aims: To examine unmet informational, physiological and health-related unmet needs among muscle invasive bladder cancer.
An Educational Intervention for Bladder Cancer Patients
Aims: To examine the feasibility of an educational intervention to enhance bladder cancer treatment decision making among newly diagnosed bladder cancer patients.
The personal patient profile decision support for patients with bladder cancer
Aims: To examine the feasibility and acceptability of the Personal Patient Profile – Bladder Cancer (P3-BC) intervention in serving as a personalized, value-based decisional tool for bladder cancer patients undergoing radical cystectomy (bladder removal) and urinary diversion.

Fellowship, The Cancer Institute of New Jersey

PhD, Free University of Berlin

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Mohamed did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.